Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders??? Equity (Unaudited)

v3.22.1
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) - USD ($)
Common Stock
Additional Paid In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2020 $ 14,393 $ 35,491,462 $ (31,519,789) $ 3,986,066
Balance (in Shares) at Dec. 31, 2020 14,393,100      
Equity-based compensation - stock option expense 473,787 473,787
Equity-based compensation - stock issuances to consultants and employees $ 350 850,550 850,900
Equity-based compensation - stock issuances to consultants and employees (in Shares) 350,000      
Warrants exercised $ 712 1,424,288 1,425,000
Warrants exercised (in Shares) 712,500      
Stock options exercised $ 10 14,490 14,500
Stock options exercised (in Shares) 10,000      
Stock issued as consideration for acquisition $ 700 1,059,450 1,060,150
Stock issued as consideration for acquisition (in Shares) 699,980      
Sale of common stock and warrants, net of transaction costs $ 1,105 2,639,898 2,641,003
Sale of common stock and warrants, net of transaction costs (in Shares) 1,104,297      
Net loss (4,833,764) (4,833,764)
Balance at Mar. 31, 2021 $ 17,270 41,953,925 (36,353,553) 5,617,642
Balance (in Shares) at Mar. 31, 2021 17,269,877      
Balance at Dec. 31, 2021 $ 20,947 54,429,979 (50,943,115) 3,507,811
Balance (in Shares) at Dec. 31, 2021 20,946,712      
Equity-based compensation - stock option expense 567,189 567,189
Equity-based compensation - stock issuances to consultants and employees $ 450 415,973 416,423
Equity-based compensation - stock issuances to consultants and employees (in Shares) 450,000      
Sale of common stock and warrants, net of transaction costs $ 2,322 9,121,419 9,123,741
Sale of common stock and warrants, net of transaction costs (in Shares) 2,322,250      
Net loss (2,907,839) (2,907,839)
Balance at Mar. 31, 2022 $ 23,719 $ 64,534,560 $ (53,850,954) $ 10,707,325
Balance (in Shares) at Mar. 31, 2022 23,718,962